Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocortisone sodium succinate is a highly water-soluble ester of hydrocortisone used as an anti-inflammatory and immunosuppressive glucocorticoid. It acts by mimicking endogenous cortisol, binding to glucocorticoid receptors to modulate gene expression and suppress inflammation and immune responses. This formulation allows for rapid intravenous or intramuscular administration in emergency situations where high blood levels of corticosteroid are needed quickly. It is indicated for severe allergic reactions, dermatologic diseases, endocrine disorders (including adrenocortical insufficiency), gastrointestinal diseases, hematological disorders, neoplastic diseases (as palliative therapy), nervous system conditions (such as cerebral edema), ophthalmic diseases, renal disease (e.g., nephrotic syndrome), respiratory conditions (e.g., asthma exacerbations), rheumatic disorders (e.g., rheumatoid arthritis), and other acute or chronic inflammatory states[1][2][5][6]. Hydrocortisone sodium succinate has both glucocorticoid and mineralocorticoid activity[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone sodium succinate.